This article shows that the benefit of ADT, when used in conjunction with radiotherapy, varies depending on one’s comorbidity and risk of death from causes other than prostate cancer itself. This study followed 4550 men with intermediate- and high-risk prostate cancer for a minimum of two years after starting ADT. In this study, the benefit of ADT in reducing the number of deaths specifically from prostate cancer was cancelled out by the increased incidence of death from other causes. Overall, for prostate cancer patients who are not otherwise in good health, ADT may not improve what matters most; i.e., overall survival.
Rose BS, Chen MH, Wu J, Braccioforte MH, Moran BJ, Doseretz DE, Katin MJ, Ross RH, Salenius SA, D'Amico AV. 2016. Androgen deprivation therapy use in the setting of high-dose radiation therapy and the risk of prostate cancer-specific mortality stratified by the extent of competing mortality. Int J Radiat Oncol Biol Phys 96(4):778-784. www.ncbi.nlm.nih.gov/pubmed/27788950